ECOG-ACRIN Cancer Research Group clinical trial pipeline

9 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 6 with minor changes only.

1. Notable

   Cancer and Blood Pressure Management, CARISMA Study

   Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027

   ECOG-ACRIN Cancer Research Group·Not applicable· NCT04467021· Registry history of NCT04467021 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

2. Notable

   Less Invasive Procedures With the Current Standard of Care…Less Invasive Procedures With the Current Standard of Care · Early-Stage Melanoma

   Primary endpoint(s) modified

   Also in this update: Sponsor changed: Eastern Cooperative Oncology Group to ECOG-ACRIN Cancer Research Group; Recruitment opened

   ECOG-ACRIN Cancer Research Group·Phase 3· NCT07068074· Registry history of NCT07068074 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

3. Notable

   Financial Burden Assessment · Stage I-III Colon or Rectal Cancer…Financial Burden Assessment · Stage I-III Colon or Rectal Cancer Undergoing Treatment

   Primary completion moved earlier from Dec 31, 2023 to Oct 13, 2021

   ECOG-ACRIN Cancer Research Group·Not specified· NCT03516942· Registry history of NCT03516942 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.